Novel Blood Oxygenator Homogeneous Membranes

新型血液氧合器均质膜

• 批准号: 6933625
• 负责人: John J Bowser
• 金额: $ 13.17万
• 依托单位: COMPACT MEMBRANE SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6933625
• 关键词: artificial membranes; bioengineering /biomedical engineering; biomaterial compatibility; biomaterial development /preparation; biomaterial evaluation; biotechnology; blood oxygenator; extracorporeal circulation

DESCRIPTION (provided by applicant): Long-term blood oxygenators (BO) therapy requires non-porous membranes to limit BO wet out. Compact Membrane Systems (CMS) has identified (1) novel materials that can minimize wet out (while simultaneously maintaining needed gas-liquid transport of gases) and (2) a novel fabrication technique to make these materials into BO. In this Phase I program, CMS will combine these novel materials with novel fabrication technique to show the feasibility of an enhanced BO. We will analyze the system compared to existing BO controls for overall oxygen mass transfer and long-term stability. In-vitro testing will provide key performance and biocompatibility data. Parallel in-vivo studies (successfully completed in other programs) will provide key additional information on system capabilities. While CMS is confident that the novel fabrication technique can be applied to the novel materials, we have also identified parallel fabrication routes if the original process does not work.

描述（由申请人提供）： 长期血氧合器 (BO) 治疗需要无孔膜来限制 BO 浸湿。紧凑型膜系统 (CMS) 已确定 (1) 可以最大程度地减少润湿（同时保持所需的气体气液传输）的新型材料和 (2) 将这些材料制成 BO 的新型制造技术。 在第一阶段计划中，CMS 将把这些新型材料与新型制造技术相结合，以展示增强型 BO 的可行性。我们将分析该系统与现有 BO 控制的整体氧气传质和长期稳定性。 体外测试将提供关键性能和生物相容性数据。并行体内研究（在其他项目中成功完成）将提供有关系统功能的关键附加信息。虽然 CMS 相信新型制造技术可以应用于新型材料，但如果原始工艺不起作用，我们也确定了并行制造路线。